N-(3-((3-(trifluoromethyl)phenyl)selanyl)prop-2-yn-1-yl) benzamide induces antidepressant-like effect in mice: involvement of the serotonergic system
- PMID: 38635075
- DOI: 10.1007/s00213-024-06588-8
N-(3-((3-(trifluoromethyl)phenyl)selanyl)prop-2-yn-1-yl) benzamide induces antidepressant-like effect in mice: involvement of the serotonergic system
Abstract
Rationale: Major Depressive Disorder (MDD) significantly impairs the quality of life for those affected. While the exact causes of MDD are not fully understood, the deficit of monoamines, especially serotonin and noradrenaline, is widely accepted. Resistance to long-term treatments and adverse effects are often observed, highlighting the need for new pharmacological therapies. Synthetic organic compounds containing selenium have exhibited pharmacological properties, including potential antidepressant effects.
Objective: To evaluate the antidepressant-like effect of N-(3-((3-(trifluoromethyl)phenyl)selenyl)prop-2-yn-1-yl) benzamide (CF3SePB) in mice and the involvement of the serotonergic and noradrenergic systems.
Methods: Male Swiss mice were treated with CF3SePB (1-50 mg/kg, i.g.) and 30 min later the forced swimming test (FST) or tail suspension test (TST) was performed. To investigate the involvement of the serotonergic and noradrenergic systems in the antidepressant-like effect of CF3SePB, mice were pre-treated with p-CPA (a 5-HT depletor, 100 mg/kg, i.p.) or the receptor antagonists WAY100635 (0.1 mg/kg, s.c., a 5-HT1A receptor antagonist), ketanserin (1 mg/kg, i.p., a 5-HT2A/2C receptor antagonist), ondansetron (1 mg/kg, i.p., a 5-HT3 receptor antagonist), GR110838 (0.1 mg/kg, i.p., a 5-HT4 receptor antagonist), prazosin (1 mg/kg, i.p., an α1-adrenergic receptor antagonist), yohimbine (1 mg/kg, i.p., an α2-adrenergic receptor antagonist) and propranolol (2 mg/kg, i.p., a non-selective beta-adrenergic receptor antagonist) at specific times before CF3SePB (50 mg/kg, i.g.), and after 30 min of CF3SePB administration the FST was performed.
Results: CF3SePB showed an antidepressant-like effect in both FST and TST and this effect was related to the modulation of the serotonergic system, specially the 5-HT1A and 5-HT3 receptors. None of the noradrenergic antagonists prevented the antidepressant-like effect of CF3SePB. The compound exhibited a low potential for inducing acute toxicity in adult female Swiss mice.
Conclusion: This study pointed a new compound with antidepressant-like effect, and it could be considered for the development of new antidepressants.
Keywords: Benzamide; Depression; Mice; Noradrenergic system; Selenium; Serotonergic system.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
Dopaminergic receptors involvement in the antidepressant-like effect of N-(3-((3-(trifluoromethyl)phenyl)selanyl)prop-2-yn-1-yl) benzamide in mice.Neurosci Lett. 2025 Feb 16;849:138144. doi: 10.1016/j.neulet.2025.138144. Epub 2025 Jan 29. Neurosci Lett. 2025. PMID: 39889880
-
Antidepressant-like effect of a selenopropargylic benzamide in mice: involvement of the serotonergic system.Psychopharmacology (Berl). 2020 Oct;237(10):3149-3159. doi: 10.1007/s00213-020-05600-1. Epub 2020 Jul 3. Psychopharmacology (Berl). 2020. PMID: 32617647
-
Dopaminergic Modulation and Computational ADMET Insights for the Antidepressant-like Effect of N-(3-(Phenylselanyl)prop-2-yn-1-yl)benzamide.ACS Chem Neurosci. 2024 May 1;15(9):1904-1914. doi: 10.1021/acschemneuro.4c00092. Epub 2024 Apr 19. ACS Chem Neurosci. 2024. PMID: 38639539
-
The need for guidance in antidepressant drug development: Revisiting the role of the forced swim test and tail suspension test.Regul Toxicol Pharmacol. 2024 Aug;151:105666. doi: 10.1016/j.yrtph.2024.105666. Epub 2024 Jun 27. Regul Toxicol Pharmacol. 2024. PMID: 38942190 Review.
-
Childhood and adolescent depression: why do children and adults respond differently to antidepressant drugs?Neurochem Int. 2007 Oct;51(5):246-53. doi: 10.1016/j.neuint.2007.06.025. Epub 2007 Jun 30. Neurochem Int. 2007. PMID: 17664028 Free PMC article. Review.
References
-
- Akil H, Gordon J, Hen R, Javitch J, Mayberg H, McEwen B, Meaney MJ, Nestler EJ (2018) Treatment resistant depression: a multi-scale, systems biology approach. Neurosci Biobehav Rev 84:272–288. https://doi.org/10.1016/j.neubiorev.2017.08.019 - DOI - PubMed
-
- Anghinoni JM, Birmann PT, da Rocha MJ, Gomes CS, Davies MJ, Brüning CA, Savegnago L, Lenardão EJ (2023) Recent advances in the synthesis and antioxidant activity of low molecular Mass Organoselenium. Molecules Molecules 28(21):7349. https://doi.org/10.3390/molecules28217349 - DOI - PubMed
-
- Artigas F (2015) Developments in the field of antidepressants, where do we go now? Eur Neuropsychopharmacol 25:657–670. https://doi.org/10.1016/j.euroneuro.2013.04.013 - DOI - PubMed
-
- Asif M (2016) Pharmacological potential of benzamide analogues and their uses in medicinal chemistry. Modern Chem Appl 4(4). https://doi.org/10.4172/2329-6798.1000194
-
- Assie MB, Bardin L, Auclair AL, Carilla-Durand E, Depoortere R, Koek W, Kleven MS, Colpaert F, Vacher B, Newman-Tancredi A (2010) F15599, a highly selective post-synaptic 5-HT(1A) receptor agonist: in vivo profile in behavioural models of antidepressant and serotonergic activity. Int J Neuropsychopharmacol 13:1285–1298. https://doi.org/10.1017/S1461145709991222 - DOI - PubMed
MeSH terms
Substances
Grants and funding
- 121/GR/UFFS/2021/Universidade Federal da Fronteira Sul
- 001/Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- 21/2551-0000728-1/Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul
- 21/2551-0000614-5/Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul
- 305626/2022-1/Conselho Nacional de Desenvolvimento Científico e Tecnológico
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous